M
Miri Yavzori
Researcher at Sheba Medical Center
Publications - 64
Citations - 2433
Miri Yavzori is an academic researcher from Sheba Medical Center. The author has contributed to research in topics: Infliximab & Medicine. The author has an hindex of 18, co-authored 47 publications receiving 2085 citations. Previous affiliations of Miri Yavzori include Tel Aviv University.
Papers
More filters
Journal ArticleDOI
Optimizing Anti-TNF-α Therapy: Serum Levels of Infliximab and Adalimumab Are Associated With Mucosal Healing in Patients With Inflammatory Bowel Diseases
Bella Ungar,Idan Levy,Yarden Yavne,Miri Yavzori,Orit Picard,Ella Fudim,Ronen Loebstein,Yehuda Chowers,Rami Eliakim,Uri Kopylov,Shomron Ben-Horin +10 more
TL;DR: It is proposed that serum levels of 6-10 μg/mL for infliximab and 8-12 μg/ mL for adalimumab are required to achieve mucosal healing in 80%-90% of patients with IBD, and that this could be considered as a "therapeutic window."
Journal ArticleDOI
Addition of an Immunomodulator to Infliximab Therapy Eliminates Antidrug Antibodies in Serum and Restores Clinical Response of Patients With Inflammatory Bowel Disease
Shomron Ben Horin,Matti Waterman,Uri Kopylov,Miri Yavzori,Orit Picard,Ella Fudim,Halim Awadie,Batia Weiss,Yehuda Chowers +8 more
TL;DR: The addition of immunomodulators to therapy might be helpful to patients who have lost response to anti-TNF agents owing to formation of antidrug antibodies.
Journal ArticleDOI
The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab
Bella Ungar,Yehuda Chowers,Miri Yavzori,Orit Picard,Ella Fudim,Ofir Har-Noy,Uri Kopylov,Rami Eliakim,Shomron Ben-Horin +8 more
TL;DR: Serial measurements showed that ATI development often preceded the onset of clinical flare, and survival free of clinical loss of response was enjoyed by 51% of patients, and serial measurements showed this incidence is reduced by concomitant immunomodulator even in scheduled-therapy patients.
Journal ArticleDOI
The immunogenic part of infliximab is the F(ab′)2, but measuring antibodies to the intact infliximab molecule is more clinically useful
Shomron Ben-Horin,Miri Yavzori,Lior H. Katz,Uri Kopylov,Orit Picard,Ella Fudim,Daniel Coscas,Simon Bar-Meir,Itamar Goldstein,Yehuda Chowers +9 more
TL;DR: Although Anti-F(ab′)2 antibodies showed similar test characteristics to ATI in patients losing response to infliximab, they were also detected in 61% of patients in maintained remission, thereby limiting their clinical usefulness.
Journal ArticleDOI
Cross-immunogenicity: antibodies to infliximab in Remicade-treated patients with IBD similarly recognise the biosimilar Remsima
Shomron Ben-Horin,Miri Yavzori,Itai Benhar,Ella Fudim,Orit Picard,Bella Ungar,Soo Young Lee,Sung Hwan Kim,Rami Eliakim,Yehuda Chowers +9 more
TL;DR: Anti-Remicade antibodies in patients with IBD recognise and functionally inhibit Remsima to a similar degree, suggesting similar immunogenicity and shared immunodominant epitopes on these two infliximab agents.